LifeSci Capital analyst Rahul Rakhit maintained a Hold rating on Better Therapeutics, Inc. (BTTX – Research Report) today. The company’s shares closed today at $1.04.
According to TipRanks, Rakhit is an analyst with an average return of -54.2% and a 6.98% success rate. Rakhit covers the Healthcare sector, focusing on stocks such as Better Therapeutics, Inc., DarioHealth, and Orchestra BioMed Holdings.
Better Therapeutics, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $7.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $2.80 and a one-year low of $0.59. Currently, Better Therapeutics, Inc. has an average volume of 247.4K.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BTTX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mountain Crest Acquisition Corp II is a blank check company.
Read More on BTTX:
